From cancer genomics to cancer immunotherapy: Toward second-generation tumor antigens

Trends in Immunology

Volumn 22, Issue 9, 2001, Pages 516-523

  Schultze, Joachim L ^a   Vonderheide, Robert H ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELANOMA ANTIGEN; PEPTIDE; PROTEIN P53; PROTEINASE; RAS PROTEIN; RECOMBINANT RNA; REVERSE TRANSCRIPTASE TELOMERASE; TUMOR REJECTION ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN DETECTION; BINDING SITE; CANCER; CANCER CELL; CANCER GENETICS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL LEVEL; CELLULAR IMMUNITY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; MASS SPECTROMETRY; NONHUMAN; PEPTIDE ANALYSIS; PROTEIN ANALYSIS; REVIEW; SCREENING;

ANTIGENS, NEOPLASM; DNA, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 0035451392     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(01)02015-4     Document Type: Review

References (57)

1. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma
2. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
3. A listing of human tumor antigens recognized by T cells
4. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II
5. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
6. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
7. T-cell immunotherapy of cancer
8. T-cell clones specific for p21 ras-derived peptides: Characterization of their fine specificity and HLA restriction
9. T-cell immunity to the joining region of p210BCR-ABL protein
10. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
11. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
12. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
13. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene
14. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
15. Vaccine implications of folate binding protein, a novel cytotoxic T-lymphocyte-recognized antigen system in epithelial cancers
16. + T effector cells by dendritic cells pulsed with protein or selected peptides
17. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies
18. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
19. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes
20. Self-tolerance and the composition of the T-cell repertoire
21. The makings of a tumor rejection antigen
22. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides
23. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T-lymphocyte responses in patients with acute hepatitis
24. Identification of HLA-A3- and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C
25. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif
26. Degenerate cytotoxic T-cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles
27. + T cells in HLA-transgenic mice and humans
28. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis
29. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection
30. Our genome unveiled
31. Signal transduction as a drug-discovery platform
32. Proteomics: A new approach to the study of disease
33. Gene expression profiling: Monitoring transcription and translation products using DNA microarrays and proteomics
34. Gene expression profiles in normal and cancer cells
35. Serial analysis of gene expression
36. Genomics, gene expression and DNA arrays
37. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
38. Positive selection of candidate tumor-suppressor genes by subtractive hybridization
39. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
40. Targeting p53 as a general tumor antigen
41. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
42. Inducing autoimmune disease to treat cancer
43. + cytotoxic T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
44. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
45. Specific association of human telomerase activity with immortal cells and cancer
46. Creation of human tumour cells with defined genetic elements
47. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse
48. Inhibition of telomerase limits the growth of human cancer cells
49. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes
50. Induction of cytotoxic T-cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA-transfected dendritic cells
51. Active immunization against cancer cells: Impediments and advances
52. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA
53. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors
54. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
55. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
56. Cancer control in susceptible groups: Opportunities and challenges
57. Searching for genetic determinants in the new millennium